Clinical studies recruiting near Pamplona

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · Clinica Universidad de Navarra · Pfizer · NCT05020236 Observational Study Protocol: LIVER-R
Phase N/A · Research Site · AstraZeneca · NCT06252753 A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Complejo Hospitalario de Navarra · Eli Lilly and Company · NCT07218380 Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT05755386 A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients Wit
Phase 1 · Clinica Universidad De Navarra · eleva GmbH · NCT07483827 Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
Phase N/A · Hospital Universitario de Navarra · Spanish Oncology Genito-Urinary Group · NCT06724159 Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · Clinica Universidad de Navarra · Miltenyi Biomedicine GmbH · NCT04844866 Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Phase 1 · Clinica Universidad de Nevarra · Ichnos Sciences SA · NCT05862012 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Gr
Phase 2 · Clinica Universidad de Navarra - Pamplona /ID# 275742 · AbbVie · NCT06682988 Spanish Series of Patients Treated With the Radionuclide Lutetium177
Phase N/A · Clínica Universidad de Navarra · Sociedad Española de Medicina Nuclear e Imagen Molecular · NCT04949282 A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Com
Phase 1/Phase 2 · Research Site · AstraZeneca · NCT06188520 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Clinica Universitaria de Navarra · Hoffmann-La Roche · NCT06793215 A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit
Phase 1/Phase 2 · Local Institution - 0014 · Bristol-Myers Squibb · NCT07291076 Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · Universidad de Navarra · CellCentric Ltd. · NCT04068597 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Hospital de Navarra · Amgen · NCT07037433 A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advance
Phase 1/Phase 2 · GSK Investigational Site · GlaxoSmithKline · NCT06885034 Spanish Registry of Esophagogastric Cancer
Phase N/A · Hospital Universitario de Navarra · Fundación Sociedad Española de Oncologia Médica · NCT04958720 A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary
Phase N/A · Clínica Universidad de Navarra · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT06686615 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Phase 1 · Clinica Universidad de Navarra · Genmab · NCT07387068 A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06581198 Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
Phase N/A · Clínica Universidad de Navarra - Hospital · Biobizkaia Health Research Institute · NCT07240038 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · Complejo Hospitalario de Navarra · Eli Lilly and Company · NCT06890598 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · Local Institution - 4108 · Turning Point Therapeutics, Inc. · NCT03093116 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · Hospital Universitario de Navarra · Regeneron Pharmaceuticals · NCT06091865 Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · Clinica Universidad de Navarra · Amgen · NCT04221542 A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Phase 3 · Hospital Universitario de Navarra · Longboard Pharmaceuticals · NCT06660394 Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcera
Phase 3 · Complejo Hospitalario de Navarra · Eli Lilly and Company · NCT06937086 Better4All Personalized Intervention Pilot Study
NA · Universidad de Navarra (Unav) · Harokopio University · NCT07120802 A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymph
Phase 3 · Clinica Universitaria De Navarra · Loxo Oncology, Inc. · NCT05254743 A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Phase 3 · Clinica Universidad de Navarra · Bristol-Myers Squibb · NCT06976216

Look up another city

Look up another condition